Advertisement

Central European Journal of Chemistry

, Volume 3, Issue 3, pp 520–536 | Cite as

Indirect spectrophotometric determination of diltiazem hydrochloride in pure form and pharmaceutical formulations

  • Akram M. El-Didamony
Article
  • 74 Downloads

Abstract

Three simple, accurate, and sensitive spectrophotometric methods (A, B and C) have been described for the indirect assay of diltiazem hydrochloride (DIL.HCl), either in pure form or in pharmaceutical formulations. The first method (A) is based on the oxidation of DIL.HCl by N-bromosuccinimide (NBS) and determination of unconsumed NBS by measuring the decrease in absorbance of amaranth dye (AM) at a suitable λ max =521 nm. Other methods (B) and (C) involve the addition of excess cerric ammonium sulfate (CAS) and subsequent determination of the unconsumed oxidant by a decrease in the red color of chromotrope 2R (C2R) at a suitable λ max =528 nm or a decrease in the orange-pink color of rhodamine 6G (Rh6G) at λ max =525 nm, respectively. Regression analysis of Beer-Lambert plots showed good correlation in the concentration ranges 3.0–9.0, 3.5–7.0 and 3.5–6.3 μg ml−1 for methods A, B and C, respectively. The apparent molar absorptivity, Sandell's sensitivity, detection and quantification limits were calculated. The proposed methods have been applied successfully for the analysis of the drug in its pure form and its dosage form. No interference was observed from a common pharmaceutical adjuvant. Statistical comparison of the results with the reference method shows excellent agreement and indicates no significant difference in accuracy and precision.

Keywords

spectrophotometry Diltiazem HCl oxidation reaction N-bromosuccinimide cerric ammonium sulfate pharmaceutical formulations 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    C.A. Fisher, M.F. Josephson, Y.T. Wacht-Fogel, R.W. Coleman and V.P. Addonizio: “Verapamil and diltiazem as antiplatelet agents, spectrum and mechanisms of activity”, Circulation, Vol. 68, (1983), pp. 318.Google Scholar
  2. [2]
    T. Funyu, K. Nigawara, K. Ohno, W. Hamada and Y. Yagihashi: “Effects of benzothiazepine derivative on blood pressure, excretion of electrolytes and plasma rennin activities”, Clin. Ther., Vol. 3, (1981), pp. 456–466.Google Scholar
  3. [3]
    British Pharmacopoeia, Vol. I, Her Majestys Stationary Office, London, 1998.Google Scholar
  4. [4]
    The United States Pharmacopoeia, The United States Pharmacopoeia Convention, 22nd ed., Rockville, 1990.Google Scholar
  5. [5]
    V. Rovel, M. Miltchard and P.L. Morselli: “Simple, sensitive and specific gas chromatographic method for the quantification of diltiazem in human body fluids”, J. Chromatogr., Vol. 138, (1977), pp. 391–398.CrossRefGoogle Scholar
  6. [6]
    J.P. Clozel, G. Caille, Y. Taeymans, P. Theroux, P. Biron and J.G Besner: “Improved gas chromatographic determination of diltiazem and deacetyldiltiazem in human plasma”, J. Pharm. Sci., Vol. 73, (1984), pp. 207–209.CrossRefGoogle Scholar
  7. [7]
    O. Grech-Belanger, E. Leboeuf and S. Langlois: “Assay of diltiazem and deacetyldiltiazem by capillary gas chromatography”, J. Chromatogr., Vol. 417, (1987), pp. 89–98.Google Scholar
  8. [8]
    Y. Kuwahara and H. Nishi: “Fast drug analysis by capillary electrophoresis, content uniformity and assay for diltiazem tablets and trimetoquinol tablets”, Yakugaku Zasshi, Vol. 118, (1998), pp. 456–463.Google Scholar
  9. [9]
    G.J. Vergote, C. Vervaet, J.P. Remon, T. Haemers and F. Verpoort: “Near-infrared FT-Raman spectroscopy as a rapid analytical tool for the determination of diltiazem hydrochloride in tablets”, Eur. J. Pharm. Sci., Vol. 16, (2002), pp. 63–67.CrossRefGoogle Scholar
  10. [10]
    J. Wang, P.A. Farias and J.S. Mahmoud: “Measurements of low concentrations of diltiazem by adsorptive stripping voltammetry and flow amperometry”, Analyst, Vol. 111, (1986), pp. 837–839.CrossRefGoogle Scholar
  11. [11]
    R.E. Wiens, D.J. Runser, J.P. Lacz and D.C. Dimmitt: “Quantitation of diltiazem and desacetyldiltiazem in dog plasma by high-performance liquid chromatography”, J. Pharm. Sci., Vol. 73, (1984), pp. 688–699.CrossRefGoogle Scholar
  12. [12]
    J.P. Clozel, G. Caille, Y. Toeymans, P. Theroux, P. Biron and F. Trudel: “High-performance liquid chromatographic determination of diltiazem and six of its metabolites in human urine”, J. Pharm. Sci., Vol. 73, (1984), pp. 771–773.CrossRefGoogle Scholar
  13. [13]
    D.R. Abernethy, J.B. Schwartz and E.L. Todd: “Diltiazem and desacetyldiltiazem analysis in human plasma using high-performance liquid chromatography: improved sensitivity without derivation”, J. Chromatogr., Vol. 342, (1985), pp. 216–220.Google Scholar
  14. [14]
    L.M. Dube, N. Mousseau and I.J. McGilveray: “High-performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma: evaluation of their stability”, J. Chromatogr., Vol. 430, (1988), pp. 103–111.Google Scholar
  15. [15]
    S. Boucher, F. Varin, Y. Theoret, P. Du Souich and G. Caille: “High-performance liquid chromatographic method for the determination of diltiazem and two of its metabolites in human plasma: application to a new sustained release formulation”, J. Pharm. Biomed. Anal., Vol. 7, (1989), pp. 1925–1930.CrossRefGoogle Scholar
  16. [16]
    P.V. Devarajan and V.V. Dhavse: “High-performance thin-layer chromatographic determination of diltiazem hydrochloride as bulk drug and in pharmaceutical preparations”, J. Chromatogr., B: Biomed. Appl., Vol. 706, (1998), pp. 362–366.CrossRefGoogle Scholar
  17. [17]
    P.M. Lacroix, N. Beaulieu, T.D. Cyr and E.G. Lovering: “High-performance liquid chromatography method for assay of diltiazem hydrochloride and its related compounds in bulk drug and finished tablets”, J. Pharm. Sci., Vol. 78, (1989), pp. 243–246.CrossRefGoogle Scholar
  18. [18]
    P.M. Lacroix, N. Beaulieu, T.D. Cyr and E.G. Lovering: “High-performance liquid chromatography method for assay of diltiazem hydrochloride and its related compounds in bulk drug and finished tablets”, J. Pharm. Sci., Vol. 78, (1989), pp. 243–246.CrossRefGoogle Scholar
  19. [19]
    Y. Shah, S. Khanna, V.S. Dighe and K.C. Jindal: “High-performance liquid chromatographic determination of diltiazem hydrochloride in tablets”, Indian Drugs, Vol. 27, (1990), pp. 363–364.Google Scholar
  20. [20]
    R.S. Chaudhary, S.S. Gangwal, M.K. Avachat, Y.N. Shah and K.C. Jindal: “Determination of diltiazem hydrochloride in human serum by high-performance liquid chromatography”, J. Chromatogr., Vol. 614, (1993), pp. 261–266.Google Scholar
  21. [21]
    Y.S.R. Krishnaiah and S.S. Patro: “Determination of diltiazem hydrochloride in human plasms by high-performance liquid chromatography”, Indian Drug, Vol. 37, (2000), pp. 570–573.Google Scholar
  22. [22]
    B. Chankvetadze, I. Kartozia and G. Blaschke: “Simultaneous enantioseparation of cis- diltiazem hydrochloride and its metabolite cis- desacetyldiltiazem using high-performance liquid chromatography and capillary electrophoresis”, J. Pharm. Biomed. Anal., Vol. 27, (2002), pp. 161–166.CrossRefGoogle Scholar
  23. [23]
    D. Zendelovska, T. Stafilov and M. Stefova: “High-performance liquid chromatographic determination of diltiazem in human plasma after solid-phase and liquid-liquid extraction”, Anal. Bioanal. Chem., Vol. 376, (2003), pp. 848–853.CrossRefGoogle Scholar
  24. [24]
    R. Bindu and A.K. Chandrasekharan: “Colorimetric determination of diltiazem hydrochloride in pharmaceutical formulations”, Indian Drugs, Vol. 31, (1994), pp. 168–169.Google Scholar
  25. [25]
    M.M. Ayad, A. Shalaby, H.E. Abdellatef and M.M. Hosny: “New colorimetric method for the determination of trazodone HCl, famotidine and diltiazem HCl in their pharmaceutical dosage forms”, Anal. Bioanal. Chem., Vol. 376, (2003), pp. 710–714.CrossRefGoogle Scholar
  26. [26]
    B.V. Kamath and K. Shivram: “Extractive spectrophotometric method for the determination of diltiazem hydrochroide in its dosge forms”, Indian Drugs, Vol. 29, (1991), pp. 50–52.Google Scholar
  27. [27]
    D. Zivanov-Stakic, D. Agbaba, S. Vladimirov and L.J. Ciric: “Spectrophotometric determination of diltiazem in dosage forms”, Farmaco, Vol. 47, (1992), pp. 393–396.Google Scholar
  28. [28]
    Y.K. Agrawal, K. Shivramchanda and B.E. Rao: “Spectrophotometric methods for the determination of dilitiazem in pharmaceutical preparations”, Indian J. Pharm. Sci., Vol. 54, (1992), pp. 218–221.Google Scholar
  29. [29]
    B.V. Kamath, K. Shivram and A.C. Shah: “Selective spectrophotometric determination of diltiazem hydrochloride in tablets”, J. Pharm. Biomed. Anal., Vol. 11, (1993), pp. 407–409.CrossRefGoogle Scholar
  30. [30]
    K. Sreedhar, C.S.P. Sastry, M.N. Reddy and D.G. Sankar: “Extractive spectrophotometric determinations of diltiazem hydrochloride”, Indian Drugs, Vol. 32, (1995), pp. 90–92.Google Scholar
  31. [31]
    N. Rahman and S.N. Hejaz-Azmi: “Extractive spectrophotometric methods for determination of diltiazem HCl in pharmaceutical formulations using bromothymol blue, bromophenol blue and bromocresol green”, J. Pharm. Biomed. Anal., Vol. 24, (2000), pp. 33–41.CrossRefGoogle Scholar
  32. [32]
    N. Rahman and S.N.H. Azmi: “Spectrophotometric determination of diltiazem hydrochloride with sodium metavanadate”, Microchem. J., Vol. 65, (2000), pp. 39–43.CrossRefGoogle Scholar
  33. [33]
    V.V. Nalimov: The application of mathematical statistics to chemical analysis, Pergamon Press, Oxford, 1963.Google Scholar
  34. [34]
    J.C. Miller and J.N. Miller: “Significance tests”, In: Statistics for analytical chemistry, 3th ed., Ellis Horwood, Chichester, 1993.Google Scholar

Copyright information

© Central European Science Journals 2005

Authors and Affiliations

  • Akram M. El-Didamony
    • 1
  1. 1.Department of Chemistry, Faculty of ScienceZagazig UniversityZagazigEgypt

Personalised recommendations